Pasar al contenido principal

MODIFICACION DE LA COMUNICACION INTERCELULAR ENTRE CELULAS INMUNES Y DE MIELOMA PARA MEJORAR LA SENSIBILIDAD A INMUNOTERAPIA Y TRATAMIENTOS CONVENCIONALES

PI17/01043

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PRIVADA CLINIC
Centro realización HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preclinical development of a humanized chimeric antigen receptor against B-cell maturation antigen for multiple myeloma

  • Pérez-Amill, Lorena|||0000-0003-0674-4660
  • Suñé, Guillermo|||0000-0002-4034-4348
  • Antoñana Vildosola, Asier|||0000-0002-1404-6398
  • Castellà, Maria
  • Najjar, Amer M.
  • Bonet, Jaume
  • Fernández-Fuentes, Narcís
  • Inogés, Susana
  • López, Ascensión
  • Bueno, Clara|||0000-0003-1442-6216
  • Juan, Manel|||0000-0002-3064-1648
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Martín-Antonio, B|||0000-0003-0612-2693
Multiple myeloma is a prevalent and incurable disease, despite the development of new and effective drugs. The recent development of chimeric antigen receptor (CAR)T cells has shown impressive results in the treatment of patients with relapsed or refractory hematologic B-cell malignancies. In recent years, B-cell maturation antigen (BCMA) has appeared as a promising antigen to target using a variety of immunotherapy treatments, including CART cells, for patients with multiple myeloma. To this end, we generated clinical-grade murine CART cells directed against BCMA, named ARI2m cells. Having demonstrated its efficacy, and in an attempt to avoid the immune rejection of CART cells by the patient, the single chain variable fragment was humanized, creating ARI2h cells. ARI2h cells showed comparable in vitro and in vivo efficacy to that of ARI2m cells, and superiority in cases of high tumor burden disease. In terms of inflammatory response, ARI2h cells produced less tumor necrosis factor-αand were associated with a milder in vivo toxicity profile. Large-scale expansion of both ARI2m and ARI2h cells was efficiently conducted following Good Manufacturing Practice guidelines, obtaining the target CART-cell dose required for treatment of multiple myeloma patients. Moreover, we demonstrated that soluble BCMA and BCMA released in vesicles both affect CAR-BCMA activity. In summary, this study sets the bases for the implementation of a clinical trial (EudraCT code: 2019-001472-11) to study the efficacy of ARI2h-cell treatment for patients with multiple myeloma.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor, Experience from an academic phase i clinical trial

  • Castellà, Maria
  • Caballero-Baños, M.
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • González-Navarro, Europa Azucena|||0000-0003-3310-5557
  • Suñé, Guillermo|||0000-0002-4034-4348
  • Antoñana Vildosola, Asier|||0000-0002-1404-6398
  • Boronat Barado, Anna
  • Marzal, Berta
  • Millán, Lucía
  • Martín-Antonio, B.|||0000-0003-0612-2693
  • Cid Colom, Jordi|||0000-0002-6406-0585
  • Lozano, Miquel|||0000-0003-2593-833X
  • García, E.
  • Tabera, Jaime|||0000-0002-5430-0151
  • Trias, E.
  • Perpiña, U.
  • Canals, Josep M.|||0000-0001-6829-7670
  • Baumann, Tycho|||0000-0003-4421-0088
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Campo, Elias|||0000-0001-9850-9793
  • Yagüe, Jordi|||0000-0001-8210-1929
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Rives, S.
  • Delgado, Julio|||0000-0002-5157-4376
  • Juan, Manel|||0000-0002-3064-1648
Development of semi-automated devices that can reduce the hands-on time and standardize the production of clinical-grade CAR T-cells, such as CliniMACS Prodigy from Miltenyi, is key to facilitate the development of CAR T-cell therapies, especially in academic institutions. However, the feasibility of manufacturing CAR T-cell products from heavily pre-treated patients with this system has not been demonstrated yet. Here we report and characterize the production of 28 CAR T-cell products in the context of a phase I clinical trial for CD19+ B-cell malignancies (NCT03144583). The system includes CD4-CD8 cell selection, lentiviral transduction and T-cell expansion using IL-7/IL-15. Twenty-seven out of 28 CAR T-cell products manufactured met the full list of specifications and were considered valid products. Ex vivo cell expansion lasted an average of 8.5 days and had a mean transduction rate of 30.6 ± 13.44%. All products obtained presented cytotoxic activity against CD19+ cells and were proficient in the secretion of pro-inflammatory cytokines. Expansion kinetics was slower in patient's cells compared to healthy donor's cells. However, product potency was comparable. CAR T-cell subset phenotype was highly variable among patients and largely determined by the initial product. T and T were the predominant T-cell phenotypes obtained. 38.7% of CAR T-cells obtained presented a TN or T phenotype, in average, which are the subsets capable of establishing a long-lasting T-cell memory in patients. An in-depth analysis to identify individual factors contributing to the optimal T-cell phenotype revealed that ex vivo cell expansion leads to reduced numbers of T, T, and T cells, while T cells increase, both due to cell expansion and CAR-expression. Overall, our results show for the first time that clinical-grade production of CAR T-cells for heavily pre-treated patients using CliniMACS Prodigy system is feasible, and that the obtained products meet the current quality standards of the field. Reduced ex vivo expansion may yield CAR T-cell products with increased persistence in vivo.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Senescence in the development and response to cancer with immunotherapy, A double-edged sword

  • Battram, Anthony M.|||0000-0002-9179-0639
  • Bachiller, Mireia|||0000-0002-6153-4722
  • Martín-Antonio, B.|||0000-0003-0612-2693
Cellular senescence was first described as a physiological tumor cell suppressor mechanism that leads to cell growth arrest with production of the senescence-associated secretory phenotype known as SASP. The main role of SASP in physiological conditions is to attract immune cells to clear senescent cells avoiding tumor development. However, senescence can be damage-associated and, depending on the nature of these stimuli, additional types of senescence have been described. In the context of cancer, damage-associated senescence has been described as a consequence of chemotherapy treatments that were initially thought of as a tumor suppressor mechanism. However, in certain contexts, senescence after chemotherapy can promote cancer progression, especially when immune cells become senescent and cannot clear senescent tumor cells. Moreover, aging itself leads to continuous inflammaging and immunosenescence which are responsible for rewiring immune cells to become defective in their functionality. Here, we define different types of senescence, pathways that activate them, and functions of SASP in these events. Additionally, we describe the role of senescence in cancer and its treatments, including how aging and chemotherapy contribute to senescence in tumor cells, before focusing on immune cell senescence and its role in cancer. Finally, we discuss potential therapeutic interventions to reverse cell senescence.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness

  • Bachiller, Mireia|||0000-0002-6153-4722
  • Pérez-Amill, Lorena|||0000-0003-0674-4660
  • Battram, Anthony M.|||0000-0002-9179-0639
  • Carné, Sebastian Ciro
  • Najjar, Amer M.
  • Verhoeyen, Els
  • Juan, Manel|||0000-0002-3064-1648
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Martín-Antonio, B.|||0000-0003-0612-2693
Background Chimeric antigen receptor (CAR)-T cell immunotherapy has modified the concept of treatment in hematological malignancies. In comparison with pediatric patients, where responses are maintained over many years, older patients, such as those with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM), present lower persistence of CAR-T cells that might be due to decreased fitness of T cells acquired with aging. Moreover, cord blood derived-NK cells (CB-NKs) and CAR-NK cells derived from CB-NK can be used ' off-the-shelf' as immune cells with antitumor properties for the treatment of cancer patients. However, to date, clinical studies have only demonstrated the safety of these therapies but not optimal efficacy. To confront the shortcomings of each therapy, we devised a novel approach consisting of simultaneous (CAR-)NK cell and CAR-T cell administration. In this setting, NK cells demonstrate an important immunoregulation of T cells that could be exploited to enhance the efficacy of CAR-T cells. Methods A combinatorial treatment based on either CAR-T and CAR-NK cells or CB-NK and CAR-T cells in two models of NHL and MM was performed. Antitumor efficacy was analyzed in vitro and in vivo, and parameters related to early activation, exhaustion and senescence of T cells were analyzed. Results We show that CAR-NK cells derived from CB-NK are only effective at high doses (high E:T ratio) and that their activity rapidly decreases over time in comparison with CAR-T cells. In comparison and to exploit the potential of ' off-the-shelf' CB-NK, we demonstrate that a low number of CB-NK in the CAR-T cell product promotes an early activation of CAR-T cells and their migration to MM cells leading to enhanced anti-MM efficacy. Moreover, cytokines related to CRS development were not increased, and importantly, CB-NK enhanced the fitness of both CAR pos and CAR neg T cells, promoting lower levels of exhaustion and senescence. Conclusion This study demonstrates a relevant immunoregulatory role of CB-NK collaborating with CAR-T cells to enhance their antitumor activity. A novel and different approach to consider in CAR-T cell immunotherapy studies is presented here with the goal to enhance the efficacy of the treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Il-15 enhances the persistence and function of bcma-targeting car-t cells compared to il-2 or il-15/il-7 by limiting car-t cell dysfunction and differentiation

  • Battram, Anthony M.|||0000-0002-9179-0639
  • Bachiller, Mireia|||0000-0002-6153-4722
  • Lopez, Victor
  • Fernandez de Larrea Rodriguez, Carlos
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Martín-Antonio, B.|||0000-0003-0612-2693
Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized the treatment of B-lymphoid malignancies. For multiple myeloma (MM), B-cell maturation antigen (BCMA)-targeted CAR-T cells have achieved outstanding complete response rates, but unfortunately, patients often relapse within a year of receiving the therapy. Increased persistence and reduced dysfunction are crucial features that enhance the durability of CAR-T cell responses. One of the factors that influence CAR-T cell in vivo longevity and loss of function, but which has not yet been extensively studied for BCMA-directed CAR-T cells, are the cytokines used during their production. We here compared the impact of IL-2, IL-15 and a combination of IL-15/IL-7 on the phenotype and function of ARI2h, an academic BCMA-directed CAR-T cell that is currently being administered to MM patients. For this study, flow cytometry, in vitro cytotoxicity assays and analysis of cytokine release were performed. In addition, ARI2h cells expanded with IL-2, IL-15, or IL-15/IL-7 were injected into MM tumor-bearing mice to assess their in vivo efficacy. We demonstrated that each of the cytokine conditions was suitable for the expansion of ARI2h cells, with clear in vitro activity. Strikingly, however, IL-15-produced ARI2h cells had improved in vivo efficacy and persistence. When explored further, it was found that IL-15 drove a less-differentiated ARI2h phenotype, ameliorated parameters related to CAR-T cell dysfunction, and lowered the release of cytokines potentially involved in cytokine release syndrome and MM progression. Moreover, we observed that IL-15 was less potent in inducing T cell senescence and DNA damage accumulation, both of which may contribute to an unfavorable CAR-T cell phenotype. These findings show the superiority of IL-15 to IL-2 and IL-15/IL-7 in the quality of anti-BCMA CAR-T cells, particularly their efficacy and persistence, and as such, could improve the duration of responses if applied to the clinical production of CAR-T cells for patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development of a Novel Anti-CD19 Chimeric Antigen Receptor, A Paradigm for an Affordable CAR T Cell Production at Academic Institutions

  • Castellà, Maria
  • Boronat, Anna|||0000-0003-0852-3634
  • Martín-Ibáñez, Raquel
  • Rodríguez, Vanina
  • Suñé, Guillermo|||0000-0002-4034-4348
  • Caballero Baños, Miguel|||0000-0002-2313-7988
  • Marzal, Berta
  • Pérez-Amill, Lorena|||0000-0003-0674-4660
  • Martín-Antonio, B.|||0000-0003-0612-2693
  • Castaño Cardoso, Julio|||0000-0002-0712-5856
  • Bueno, Clara|||0000-0003-1442-6216
  • Balagué, Olga|||0000-0002-5099-3675
  • González-Navarro, Europa Azucena|||0000-0003-3310-5557
  • Serra-Pages, Carles
  • Engel, Pablo|||0000-0001-8410-252X
  • Vilella, Ramon
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Ortiz-Maldonado, Valentín|||0000-0003-4699-6862
  • Cid, Joan|||0000-0001-5445-4508
  • Tabera, Jaime|||0000-0002-5430-0151
  • Canals, Josep M.|||0000-0001-6829-7670
  • Lozano, Miquel|||0000-0003-2593-833X
  • Baumann, Tycho|||0000-0003-4421-0088
  • Vilarrodona, Ana|||0000-0001-6984-1834
  • Trias, Esteve|||0000-0001-7635-4428
  • Campo, Elias|||0000-0001-9850-9793
  • Menéndez Bujan, Pablo|||0000-0001-9372-1007
  • Urbano Ispizua, Álvaro|||0000-0002-7529-9399
  • Yagüe, Jordi|||0000-0001-8210-1929
  • Pérez-Galán, Patricia|||0000-0003-3895-5024
  • Rives, Susana|||0000-0002-5658-1831
  • Delgado, Julio|||0000-0002-5157-4376
  • Juan, Manel|||0000-0002-3064-1648
Genetically modifying autologous T cells to express an anti-CD19 chimeric antigen receptor (CAR) has shown impressive response rates for the treatment of CD19+ B cell malignancies in several clinical trials (CTs). Making this treatment available to our patients prompted us to develop a novel CART19 based on our own anti-CD19 antibody (A3B1), followed by CD8 hinge and transmembrane region, 4-1BB- and CD3z-signaling domains. We show that A3B1 CAR T cells are highly cytotoxic and specific against CD19+ cells in vitro, inducing secretion of pro-inflammatory cytokines and CAR T cell proliferation. In vivo, A3B1 CAR T cells are able to fully control disease progression in an NOD.Cg-Prkdc Il2rd/SzJ (NSG) xenograph B-ALL mouse model. Based on the pre-clinical data, we conclude that our CART19 is clearly functional against CD19+ cells, to a level similar to other CAR19s currently being used in the clinic. Concurrently, we describe the implementation of our CAR T cell production system, using lentiviral vector and CliniMACS Prodigy, within a medium-sized academic institution. The results of the validation phase show our system is robust and reproducible, while maintaining a low cost that is affordable for academic institutions. Our model can serve as a paradigm for similar institutions, and it may help to make CAR T cell treatment available to all patients.